Concepedia

Natalie S. Callander

NS

146

Publications

14.4K

Citations

57

H-Index

1992

Active since

Affiliations

University of Wisconsin Carbone Cancer Center(Current)

University of Wisconsin–Madison

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Medical College of Wisconsin

Natalie S. Callander is an author at University of Wisconsin Carbone Cancer Center specializing in medicine, hematology, and oncology.

ORCID

Top concepts

Publications per year

1992–2025

146

Publications

146

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister et al. · New England Journal of Medicine · 2012 · 1.1K citations · Full text

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

S. Vincent Rajkumar, Susanna Jacobus, Natalie S. Callander et al. · The Lancet Oncology · 2009 · 930 citations · Full text

, , +8

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani et al. · The Lancet · 2016 · 842 citations

, , +6

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 772 citations

, , +6

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf et al. · New England Journal of Medicine · 2023 · 627 citations · Full text

Rows per page

1–5 of 146